

PRELIM AGENDA (SUBJECT TO CHANGE)

SATURDAY, AUGUST 8 - SUNDAY, AUGUST 9, 2026

DAY 1 - SATURDAY, AUGUST 8, 2026

02:00 PM – 02:45 PM: Registration, Exhibits, & Breakfast

02:45 PM - 03:00 PM Welcome

03:00 PM - 04:30 PM SESSION 1: PROGRESS IN TARGETED THERAPY FOR LUNG CANCER

03:00 PM - 03:15 PM: Keynote Speech

03:15 PM - 03:30 PM: Optimal Sequencing of Therapy in EGFR mutant NSCLC

03:30 PM - 03:45 PM: Targeting HER2 in NSCLC

03:45 PM - 04:00 PM: EGFR Exon 20 ins and Uncommon Mutations in NSCLC

04:00 PM - 04:15 PM: Targeting other Uncommon Oncogene Drivers

04:15 PM - 04:30 PM: Panel Discussion

04:30 PM - 05:30 PM Break & Exhibits

05:30 PM - 06:30 PM SESSION 2: NEW TARGETS & TREATMENTS IN ONCOGENE DRIVEN LUNG CANCER

05:30 PM - 05:45 PM: Keynote Speech

05:45 PM - 06:00 PM: Optimal Sequencing of Therapy in EGFR mutant NSCLC

06:00 PM - 06:15 PM: Targeting HER2 in NSCLC

06:15 PM - 06:30 PM: EGFR Exon 20 ins and Uncommon Mutations in NSCLC

DAY 2 - SUNDAY, AUGUST 9, 2026

07:00 AM – 08:00 AM Registration, Exhibits & Breakfast

08:00 PM - 08:30 PM Binaytara's Efforts in Improving Cancer Care Disparities

08:30 AM – 09:30 AM SESSION 3: IMMUNOTHERAPIES AND ADCs IN ADVANCED LUNG CANCER: WHAT'S NEXT?

08:30 AM - 08:45 AM: New Biomarkers for IO Agents in Lung Cancer

08:45 AM - 09:00 AM: Cellular Therapies in Lung Cancer

09:00 AM - 09:15 AM: Novel IO Agents in NSCLC

09:15 AM - 09:30 AM: Panel Discussion

09:30 AM – 10:00 AM Break & Exhibits

10:00 AM – 11:30 AM SESSION 4: MULTIMODALITY TREATMENT IN LUNG CANCER

10:00 AM - 10:30 AM: Keynote Speech

10:30 AM - 10:45 AM: Multistation N2 Disease: Chemo-IO -Surgery is the Best Treatment

10:45 AM - 11:00 AM: Multistation N2 Disease: Chemoradiation - IO

11:00 AM - 11:15 AM: Integrating Targeted Therapy in Early Stage and Locally Advanced NSCLC

11:15 AM - 11:30 AM: Panel Discussion

11:30 AM – 12:30 AM SESSION 5: NEW BIOMARKERS IN LUNG CANCER

11:30 AM - 11:45 AM: New Biomarkers in Immunotherapy

11:45 AM - 12:00 AM: New Biomarkers in Small Cell Lung Cancer and other Neuroendocrine Tumors

12:00 AM - 12:15 AM: Circulating Tumor DNA in Lung Cancer: Next Steps

12:15 AM - 12:30 PM: Panel Discussion

12:30 AM – 01:30 PM Lunch, Exhibits

01:30 PM – 02:45 PM SESSION 6: LATEST AND GREATEST IN SQUAMOUS LUNG CANCER, SMALL CELL LUNG CANCER, AND THYMOMA / MESOTHELIOMA

01:30 PM - 01:45 PM: Advances in SCLC and other Neuroendocrine Tumors

01:45 PM - 02:00 PM: Advances in the Treatment of Thymic Malignancies and Mesothelioma

02:00 PM - 02:15 PM: ABCs of ADCs in Lung Cancer

02:15 PM - 02:30 PM: New Target in Squamous NSCLC

02:30 PM - 02:45 PM: Panel Discussion

02:45 PM – 03:30 PM SESSION 7: IMPORTANT PATIENT POPULATIONS IN LUNG CANCER

02:45 PM - 03:00 PM: Advances in CNS Disease in Lung Cancer

03:00 PM - 03:15 PM: Special Considerations for Treatment of Lung Cancer in Older Adults

03:15 PM - 03:30 PM: Panel Discussion

03:30 PM Adjourn